H.C. Wainwright upgraded Ventyx Biosciences (VTYX) to Buy from Neutral with an $18 price target The firm says the recent acquisition from Novartis of Tourmaline highlights hsCRP biomarker for cardiovascular disease. Recent data from Ventyx’s VTX3232 Phase 2 trial for obesity and cardiovascular risk factors “largely mimics” data presented from IL-6 inhibitor pacibekitug from Tourmaline which was acquired recently by Novartis for $1.4B in September, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTYX:
- Ventyx Biosciences price target raised to $14 from $9 at Oppenheimer
- Promising Phase II Trial Results of VTX3232 Bolster Buy Rating for Ventyx Biosciences
- Midday Fly By: Tesla reports mixed Q3, Trump in talks for quantum stakes
- Video: Lackluster Tesla and IBM quarters weighing on sentiment
- Why Is Ventyx Biosciences Stock (VTYX) Up 105% Today?